Risky as hell, but I finally pulled the trigger on ONWD

{"summary": "Author discloses a 5000-share long position in ONWARD Medical (ONWD), citing H1 ARC-EX revenue up 240% YoY, 159 systems sold/supplied via paid evaluations (up 430%), 130+ US clinics and expansion into home use, with the larger bet on ARC-IM and ARC-BCI clinical programs; acknowledges cash burn and trial failure risk.", "reason": "Accepted: actionable long thesis on an identifiable listed stock with concrete catalysts (H1 revenue growth, clinic expansion, clinical programs) and stated risks.", "ideas": [{"symbol": "ONWD", "direction": "long", "thesis": "Author bought 5000 ONWD shares betting that ONWARD Medical's ARC-EX commercial traction (H1 revenue +240% YoY, 159 systems via paid evaluations, 130+ US clinics, moving into home use) plus optionality from ARC-IM and ARC-BCI clinical programs can turn it into a much bigger story than a small medical device company. The catalyst is continued clinical trial success and commercial rollout; the main stated risk is heavy cash burn and the possibility the big programs fail.", "thesis_short": "Long ONWD on ARC-EX growth and trial optionality", "quote": "H1 results just came out and ARC-EX revenue was up 240% YoY. Even crazier, 159 systems were sold/supplied through paid evaluations, up 430%. \nThey’re already in 130+ US clinics and starting to move into home use.", "confidence": 0.8, "sentiment": 0.8, "timeframe": "unspecified"}], "model": "deepseek-v4-flash"}